Residual leukemic stem cells (LSCs) are leukemia relapse-initiating cells that mediate treatment resistance in response to therapy stress. Different from normal hematopoietic stem cells (HSCs), both blasts and LSCs express T-cell immunoglobulin mucin-3 (TIM-3) on the surface.
Targeting topoisomerase 2 (TOP2) is crucial in AML, and researchers from Wakunaga Pharmaceutical Co. Ltd. have developed and tested racemic WAC-224, a quinolone TOP2 inhibitor, and (R)-WAC-224 as a potential approach for AML treatment.
Genfleet Therapeutics (Shanghai) Co. Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to advance GFH-375 (VS-7375) into a phase I/II study in patients with advanced solid tumors with KRAS G12D mutation.
Yellowstone Biosciences Ltd. has launched with a focus on soluble bispecific T-cell receptor (TCR)-based therapies for human leukocyte antigen (HLA) class II (HLA-II) targets in oncology.
Researchers from BC Cancer Research Institute (Provincial Health Services Authority) and the University of British Columbia have presented the discovery and preclinical characterization of [68Ga]LW-02050, a 68Ga-labeled hydroxamate derivative of SB3.
Among the acquired mutations in the calreticulin (CALR) gene, both 52 bp deletion (del52) and 5 bp insertion (ins5) are among the most frequent and are linked to two different types of myeloproliferative neoplasms (MPNs).
A new approach against non-small-cell lung cancer (NSCLC) has combined immunotherapy with molecularly targeted therapy to activate the immune response and inhibit oncogenic pathways, which prevented tumor progression and eliminated cancer cells. Brigham and Women’s Hospital scientists have developed nanoparticles loaded with antibody conjugates that could deliver large amounts of treatment to the tumor tissue. This new strategy could improve the results of conventional immunotherapy in these patients and reduce toxicity of existing treatments.
The annual Companies to Watch report, which was just released, looks closely at seven companies flying under the radar that are developing antibody-drug conjugates (ADCs) for treating cancer. Companies examined in the new report are Adcendo ApS, Araris Biotech AG, Go Therapeutics Inc., Heidelberg Pharma AG, Pheon Therapeutics Ltd., Tallac Therapeutics Inc. and Tubulis GmbH.
The adverse effects of PD-1 blockers on the CNS observed in cancer patients could occur through their effects on an enzyme that activates microglia. Pharmacological inhibition of the enzyme in mice reduced microglial activation and cognitive deficit without altering the antitumor capacity of the immunotherapy.
During the basic science morning track on the last day of this year’s Annual Congress of the European Hematology Association (EHA), the attention was focused on oncogenic transcription factors and complexes considered turning points within the acute myeloid leukemia (AML) arena.
RSS
